TITLE

Arigene Terminates Trimeris Offer

AUTHOR(S)
Davis, Avram
PUB. DATE
January 2010
SOURCE
Mergers & Acquisitions Report;1/4/2010, Vol. 23 Issue 1, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of South Korean entertainment company Arigene Co. Ltd. to terminate its offer to acquire Trimeris Inc. In the initial agreement, Arigene has announced its intention to purchase the outstanding shares of Trimeris for an estimated 81 million U.S. dollars. Arigene also requested an extension of the deadline to acquire the outstanding shares.
ACCESSION #
47496845

 

Related Articles

  • Pair Lighting 'Fuzeon' Merger; Trimeris, Korean Firm to Join.  // BioWorld Today;10/5/2009, Vol. 20 Issue 191, p2 

    The article reports that Trimeris Inc. has agreed to an acquisition by Arigene Co. Ltd. amounting to 81 million U.S. dollars. Shares of Trimeris rose by 37%, or 95 cents, closing at 3.53 U.S. dollars. Trimeris' merger with Arigene has been approved by its boards and stockholders. The merger is...

  • Trimeris Back to Square One as Arigene Buyout Collapses. Boggs, Jennifer // BioWorld Today;12/30/2009, Vol. 20 Issue 250, p1 

    This article reports on the decision of Trimeris Inc. to turn down a further request by Arigene Co. Ltd. to extend its tender offer into January 2010. Arigene asked for further extension because it was unable to secure financing by the original expiration date. The South Korean company then...

  • Trimeris Scrambles as Arigene Buyout Collapses.  // Bioworld Week;1/4/2010, Vol. 18 Issue 1, p3 

    The article reports on the termination of the acquisition deal between Trimeris Inc. and Arigene Co. Ltd. due to financial shortage. It states that the former has agreed to be acquired by the latter for about 81 million dollars. However, it cites that the agreement has been cancelled because...

  • Pair Lighting 'Fuzeon' Merger; Trimeris, Korean Firm to Join.  // BioWorld International;10/7/2009, Vol. 14 Issue 40, p4 

    The article reports that Trimeris Inc. is being acquired by Korean firm Arigene Co. Ltd. in a deal worth 81 million U.S. dollars. Trimeris developed Fuzeon, a drug which helps inhibit HIV, through a previous partnership with Swiss based pharmaceutical company Roche. Trimeris has experienced a...

  • Arigene terminates offer for Trimeris, cites lack of funding.  // Medical Device Daily;12/31/2009, Vol. 13 Issue 251, p3 

    The article reports on the decision of Arigene to terminate its tender offer for the outstanding common stock of Trimeris. The move was made because Arigene was unable to secure sufficient financing for the tender offer. The depositary has been instructed to return all shares of Trimeris common...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p2 

    This section offers news briefs on the biotechnology industry. A merger agreement with Trimeris Inc. was amended by Arigene Co. Ltd. to extend the tender offer for the outstanding shares of Trimeris. A 40 million U.S. dollar contract has been awarded by the U.S. Biomedical Advanced Research and...

  • OTHER NEWS TO NOTE.  // BioWorld International;10/21/2009, Vol. 14 Issue 42, p2 

    This section offers news briefs concerning the biotechnology industry. Alizyme plc stated that its administrators have sold its lead product, Cetalistat, to Norgine BV for 4.6 million British pounds. Amarin Corp. plc has completed its private placement amounting to 70 million U.S. dollars....

  • Focus on ERTs as Synageva Inks Trimeris Reverse Merger.  // Bioworld Week;6/20/2011, Vol. 19 Issue 25, p2 

    The article reports that the Synageva BioPharma Corp. planned to be stock-for-stock merger with Trimeris Inc. after it has pulled its 25 million dollar in equity financing.

  • M&A Looks Good For Stocks in 2000. Appin, Rick // Mergers & Acquisitions Report;08/16/99, Vol. 12 Issue 33, p3 

    Looks at impact of corporate merger and acquisition deals to the stocks of several firms in the year 2000. Effects on stocks in the business industry; Comment from Ralph Acampora, director of technical research at Prudential Securities; Details on the acquisition activities in the utility sector.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics